# One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

> **NCT02240108** · PHASE3 · TERMINATED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 81 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Rifaximin EIR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02240108
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10-28
- **Primary completion:** 2017-10-06
- **Final completion:** 2017-10-06
- **Target enrollment:** 81 (ACTUAL)
- **Why stopped:** The study was terminated early due to difficulty in enrollment and lack of clinical study drug access.
- **Last updated:** 2019-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02240108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02240108, "One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02240108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*